lomefloxacin has been researched along with Infections, Respiratory in 11 studies
lomefloxacin: structure given in first source
lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A comparative clinical study of lomefloxacin hydrochloride (LFLX) was performed to confirm the optimal dose of LFLX for treatment of respiratory tract infections." | 9.07 | [A clinical study on lomefloxacin to find appropriate dose levels in the treatment of respiratory tract infections]. ( Hasegawa, Y; Ichiyama, S; Ikeda, T; Nakanishi, K; Nishiwaki, K; Saka, H; Shimokata, K; Taniguchi, K; Totani, Y; Yamada, Y, 1993) |
| "Ciprofloxacin was the most active compound against Pseudomonas aeruginosa (MIC90 = 1 mg/L), followed by trovafloxacin (MIC90 = 4 mg/L)." | 5.30 | In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. ( Hoogkamp-Korstanje, JA, 1997) |
| " Compared with the data reported for young adults, the elimination half-life (12." | 5.28 | Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ( Glerum, JH; Hoepelman, AI; Kovarik, JM; Rozenberg-Arska, M; Sips, PA; Smit, JM; Verhoef, J, 1992) |
| "A comparative clinical study of lomefloxacin hydrochloride (LFLX) was performed to confirm the optimal dose of LFLX for treatment of respiratory tract infections." | 5.07 | [A clinical study on lomefloxacin to find appropriate dose levels in the treatment of respiratory tract infections]. ( Hasegawa, Y; Ichiyama, S; Ikeda, T; Nakanishi, K; Nishiwaki, K; Saka, H; Shimokata, K; Taniguchi, K; Totani, Y; Yamada, Y, 1993) |
| "The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections." | 3.67 | Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988) |
| "Lomefloxacin was suggested to be the most advantageous drug in the treatment of elderly patients with LRTI because of its easy use, practically no dependence of the pharmacokinetics on the patient age and almost no nephrotoxic action." | 2.69 | [Selection of antibacterial therapy for treatment of infections in elderly patients]. ( Belousov, IuB; Efremenkova, OV; Komarova, VP, 1998) |
| " Both fleroxacin and lomefloxacin were given orally, the dosage was 200 mg every 12 hours or 400 mg every 24 hours for 7-14 days." | 2.68 | [A clinical study in the treatment of acute bacterial infections with fleroxacin]. ( Cui, H; Hou, J; Li, J, 1996) |
| "Ciprofloxacin was the most active compound against Pseudomonas aeruginosa (MIC90 = 1 mg/L), followed by trovafloxacin (MIC90 = 4 mg/L)." | 1.30 | In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. ( Hoogkamp-Korstanje, JA, 1997) |
| "In Japan, cystic fibrosis is rare, and this patient is extremely rare because he has grown up to be a 16-year-old." | 1.29 | [A case of cystic fibrosis in a Japanese student]. ( Kitade, M; Moritaka, T; Nakanishi, N; Ueda, N, 1995) |
| " Compared with the data reported for young adults, the elimination half-life (12." | 1.28 | Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ( Glerum, JH; Hoepelman, AI; Kovarik, JM; Rozenberg-Arska, M; Sips, PA; Smit, JM; Verhoef, J, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 10 (90.91) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakanishi, N | 1 |
| Ueda, N | 1 |
| Kitade, M | 1 |
| Moritaka, T | 1 |
| Shimokata, K | 1 |
| Totani, Y | 1 |
| Ichiyama, S | 1 |
| Saka, H | 1 |
| Hasegawa, Y | 1 |
| Ikeda, T | 1 |
| Yamada, Y | 1 |
| Nishiwaki, K | 1 |
| Nakanishi, K | 1 |
| Taniguchi, K | 1 |
| Spivey, IM | 1 |
| Suzuki, T | 1 |
| Sasada, M | 1 |
| Okuma, M | 1 |
| Fukuhara, S | 1 |
| Yasuda, N | 1 |
| Amano, H | 1 |
| Kanachi, K | 1 |
| Ohno, T | 1 |
| Kawasaki, T | 1 |
| Yumoto, Y | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Hou, J | 1 |
| Li, J | 1 |
| Cui, H | 1 |
| Belousov, IuB | 1 |
| Komarova, VP | 1 |
| Efremenkova, OV | 1 |
| Mishin, VIu | 1 |
| Vasil'eva, IA | 1 |
| Martynova, LP | 1 |
| Kovarik, JM | 1 |
| Hoepelman, AI | 1 |
| Smit, JM | 1 |
| Sips, PA | 1 |
| Rozenberg-Arska, M | 1 |
| Glerum, JH | 1 |
| Verhoef, J | 1 |
| Obana, Y | 1 |
| Nishino, T | 1 |
4 trials available for lomefloxacin and Infections, Respiratory
| Article | Year |
|---|---|
[A clinical study on lomefloxacin to find appropriate dose levels in the treatment of respiratory tract infections].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Dose-Response Relations | 1993 |
[Clinical efficacy of lomefloxacin for associated infection in patients with hematological diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Female; Flu | 1997 |
[A clinical study in the treatment of acute bacterial infections with fleroxacin].
Topics: Adult; Anti-Infective Agents; Female; Fleroxacin; Fluoroquinolones; Humans; Male; Middle Aged; Quino | 1996 |
[Selection of antibacterial therapy for treatment of infections in elderly patients].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Cefaclor; Cephalosporins | 1998 |
7 other studies available for lomefloxacin and Infections, Respiratory
| Article | Year |
|---|---|
[A case of cystic fibrosis in a Japanese student].
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Amikacin; Anti-Bacterial Agents; Anti- | 1995 |
Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
Topics: Adult; Anti-Infective Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infectio | 1993 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter | 1997 |
[Efficiency of lomefloxacine in combined treatment of patients with multiresistant pulmonary tuberculosis complicated with nonspecific bronchopulmonary infection].
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Fluoroquinolones; Humans; Isoniazid; Middle Age | 1999 |
Two new fluoroquinolones.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Drug Interactions; Fluoroquinolones; Humans; Microb | 1992 |
Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Chronic Disease; Female; Fluoroquinolones; Humans; L | 1992 |
Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Experimental; Female; Fluoroquinol | 1988 |